KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Tax Provisions (2021 - 2025)

Historic Tax Provisions for Novavax (NVAX) over the last 8 years, with Q3 2025 value amounting to -$657000.0.

  • Novavax's Tax Provisions rose 3633.72% to -$657000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 7446.81%. This contributed to the annual value of $10.9 million for FY2024, which is 43589.36% up from last year.
  • Latest data reveals that Novavax reported Tax Provisions of -$657000.0 as of Q3 2025, which was up 3633.72% from $946000.0 recorded in Q2 2025.
  • In the past 5 years, Novavax's Tax Provisions ranged from a high of $16.6 million in Q4 2021 and a low of -$2.3 million during Q4 2022
  • Its 5-year average for Tax Provisions is $2.5 million, with a median of $1.7 million in 2023.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 12819.58% in 2023, then soared by 164195.8% in 2024.
  • Novavax's Tax Provisions (Quarter) stood at $16.6 million in 2021, then tumbled by 113.61% to -$2.3 million in 2022, then skyrocketed by 174.69% to $1.7 million in 2023, then soared by 341.29% to $7.4 million in 2024, then plummeted by 108.82% to -$657000.0 in 2025.
  • Its Tax Provisions stands at -$657000.0 for Q3 2025, versus $946000.0 for Q2 2025 and $1.2 million for Q1 2025.